Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
This is a multicenter Phase I/II study for patients with advanced non-small cell lung cancer who have failed PD-1/L1 therapy, aiming to evaluate the safety of ZG005 in combination with Gecacitinib in this population, as well as the preliminary efficacy of this combination regimen.
Non-small Cell Lung Cancer
BIOLOGICAL: ZG005 for Injection|DRUG: Gecacitinib Hydrochloride Tablets
Adverse Event (AE), Up to 2 years
Objective response rate (ORR), Up to 2 years
This is a multicenter Phase I/II study for patients with advanced non-small cell lung cancer who have failed PD-1/L1 therapy, aiming to evaluate the safety of ZG005 in combination with Gecacitinib in this population, as well as the preliminary efficacy of this combination regimen.